drugset / Trial / NCT04779047
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
RandomizedParallel-groupOpen-labelTreatment
Summary
Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2021-03-10
- Completion
- 2021-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | — |
| Comparator | Ivermectin | Small molecule | 36 mg | — |
| Comparator | Lopinavir | Other / unclassified | 400 mg | — |
| Comparator | Remdesivir | Small molecule | 100 mg | Intravenous |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |
| Comparator | Tocilizumab | Monoclonal antibody | 800 mg | Intravenous |